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Abstract: B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common childhood
malignancy. The two-step BCP-ALL pathogenesis requires in utero-induced chromosomal aberrations and
additional mutagenic events for overt leukemia. In mouse models, activation-induced cytidine deaminase
(AID/AICDA) was suggested to contribute to BCP-ALL pathogenesis by off-target mutagenic activity.
The role of AID in patients, however, remains unclear. Moreover, AID is usually not expressed in
precursor B-cells but in germinal center B-cells, where it is induced upon T-helper (Th) cell stimulation.
We have previously demonstrated that autologous Th-cells supportively interacted with BCP-ALL-cells.
Here, we hypothesize that this interaction additionally induces AID expression in BCP-ALL-cells, leading
to off-target mutagenic activity. We show that co-culture with autologous bone marrow Th-cells induced
high AICDA expression in primary BCP-ALL-cells. This induction was mediated by a mechanism similar
to the induction in mature B-cells involving IL-13/Stat6, CD40L/NF-฀B and TGF฀/Smad2/3 signaling.
Even though Th-cell-induced AID seemed to be active in vitro in a BCP-ALL reporter cell line, extensive
mutational signature analysis revealed no major contribution of AID activity to the mutational landscape
in BCP-ALL patients. AID activity was neither detected in mutation clusters nor in known AID targets.
Moreover, no recurrently mutated gene showed a relevant enrichment of mutations in the AID motif.
Together, the lack of AID-induced mutational consequences argues towards a Th-cell-promoted yet AID-
independent BCP-ALL pathogenesis and favors therapeutic research focusing on Th-cell-derived support
of BCP-ALL-cells rather than AID-induced effects.
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Abstract
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common childhood malignancy. The two-step BCP-
ALL pathogenesis requires in utero-induced chromosomal aberrations and additional mutagenic events for overt leukemia. 
In mouse models, activation-induced cytidine deaminase (AID/AICDA) was suggested to contribute to BCP-ALL pathogen-
esis by off-target mutagenic activity. The role of AID in patients, however, remains unclear. Moreover, AID is usually not 
expressed in precursor B-cells but in germinal center B-cells, where it is induced upon T-helper (Th) cell stimulation. We 
have previously demonstrated that autologous Th-cells supportively interacted with BCP-ALL-cells. Here, we hypothesize 
that this interaction additionally induces AID expression in BCP-ALL-cells, leading to off-target mutagenic activity. We 
show that co-culture with autologous bone marrow Th-cells induced high AICDA expression in primary BCP-ALL-cells. 
This induction was mediated by a mechanism similar to the induction in mature B-cells involving IL-13/Stat6, CD40L/NF-κB 
and TGFβ/Smad2/3 signaling. Even though Th-cell-induced AID seemed to be active in vitro in a BCP-ALL reporter cell 
line, extensive mutational signature analysis revealed no major contribution of AID activity to the mutational landscape in 
BCP-ALL patients. AID activity was neither detected in mutation clusters nor in known AID targets. Moreover, no recur-
rently mutated gene showed a relevant enrichment of mutations in the AID motif. Together, the lack of AID-induced muta-
tional consequences argues towards a Th-cell-promoted yet AID-independent BCP-ALL pathogenesis and favors therapeutic 
research focusing on Th-cell-derived support of BCP-ALL-cells rather than AID-induced effects.
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Introduction
B-cell precursor acute lymphoblastic leukemia (BCP-ALL), 
the most common pediatric malignancy [1], arises from the 
expansion of precursor B-cells in the bone marrow (BM). Its 
pathogenesis is thought to be a two-step process [2]. The first 
step is characterized by chromosomal aberrations with pre-
natal origin, such as ETV6-RUNX1 [3]. This translocation 
is present in 1–5% of newborns but only 1% thereof develop 
overt leukemia [4], i.e., after the acquisition of secondary 
mutations. Both epidemiological and recent mechanistic 
studies suggest that a delayed exposure to common infec-
tions is involved in the second step [2, 5, 6]. At a later stage 
of BCP-ALL, additional mutagenesis may induce mutations 
associated with therapy resistance [7]. The precise mecha-
nisms leading to secondary and therapy resistance-associ-
ated mutations are unclear.
The enzyme activation-induced cytidine deaminase (AID 
encoded by AICDA), usually expressed in germinal center 
(GC) B-cells, is essential for beneficial mutations in the Ig 
loci during somatic hypermutation (SHM) and class switch 
recombination (CSR). Its expression is induced upon contact 
with T-helper (Th) cells. In mature B-cells, AID also causes 
off-target mutations in proto-oncogenes, thereby contribut-
ing to both initiation and progression of B-cell malignan-
cies like chronic lymphocytic leukemia (CLL), Burkitt lym-
phoma and multiple myeloma (MM) [8–11]. In fact, AID 
expression is associated with worse outcome in a subset of 
CLL patients [9]. Although scarcely expressed in healthy 
precursor B-cells, AID accelerates overt leukemia induction 
in mouse models of BCR-ABL1 and ETV6-RUNX1 BCP-
ALL [12, 13]. Moreover, AID expression is associated with 
higher mutation load in patients with BCR-ABL1 BCP-ALL 
[14]. Interestingly, AID is not required for leukemia develop-
ment in the  Pax5+/− mouse model [15]. Thus, the presence of 
AID-induced mutations in patients with BCP-ALL subtypes 
other than BCR-ABL1 and the mechanism of aberrant AID 
expression remains unclear.
Following infections, memory Th-cells home to the BM 
[16]. We have previously shown that these BM Th-cells pro-
mote activation and proliferation of BCP-ALL-cells, thereby 
providing a mechanistic link between infections and leu-
kemia development [17]. Here, we hypothesized that Th-
cells induce AID expression, which may lead to off-target 
mutagenesis in BCP-ALL-cells and contribute to second-
ary and therapy resistance-associated mutations. Thus, we 
investigated the potential of autologous Th-cells to induce 
AID expression in BCP-ALL-cells upon co-culture and the 




The study was performed in accordance with the 1964 dec-
laration of Helsinki and approved by the regional ethics 
committee (Kantonale Ethikkommision Zürich, KEK-ZH 
Nr. StV40/05 and Nr. 2014-0701). BM mononuclear cells 
(BMMCs) were obtained from BM aspirates of pediatric 
BCP-ALL patients at the University Children’s Hospi-
tal Zurich and from the Biobank of the Swiss Paediatric 
Oncology Group (SPOG) after informed consent. ALL671 
BMMCs were derived from an NSG xenograft and a gift 
from the group of Jean-Pierre Bourquin and Beat Born-
hauser (University Children’s Hospital Zurich). Palatine 
tonsils were derived from healthy children after routine 
tonsillectomy at the University Children’s Hospital Zurich 
after informed consent.
Cell culture
Lymphoblastoid cell lines (LCLs) were generated from ton-
sillar mononuclear cells as described [18]. Th-cells were 
isolated from BMMCs and expanded as described [17]. 
SD1 (gift from Beat Schäfer, University Children’s Hospi-
tal Zurich), RS4;11 (DSMZ), Nalm6 (gift from Jean-Pierre 
Bourquin, University Children’s Hospital Zurich) cells and 
LCLs were cultured in RPMI-1640 (Sigma Aldrich) sup-
plemented with 10% heat-inactivated fetal bovine serum 
(hi-FBS, Sigma Aldrich), GlutaMAX™-I, 100 U/ml Peni-
cillin, 100 μg/ml Streptomycin, (all gibco), hereafter called 
c-RPMI. TOM1 (DSMZ) cells were cultured in cRPMI 
supplemented with additional 10% hi-FBS. HEK293-T 
(gift from Beat Schäfer, University Children’s Hospital 
Zurich) cells were cultured in Dulbecco’s Modified Eagle’s 
Medium–high glucose (Sigma Aldrich) supplemented with 
10% hi-FBS, GlutaMAX™-I, and Penicillin–Streptomycin. 
All cells were cultured at 37 °C in 5%  CO2.
Co‑cultures
Rested Th-cells (> 95% purity by flow cytometry) were co-
cultured with CD4neg BMMCs at a 1:1 ratio in c-RPMI with 
20 U/ml human recombinant IL-2 (Roche Diagnostics) in 
presence or absence of Dynabeads™ Human T-Activator 
CD3/CD28 (gibco). After co-culture, leukemia cells were 
separated with CD19 microbeads and two consecutive col-
umns (Miltenyi Biotec).  CD19+ isolation efficiency was 
pre-validated using tonsillar B-cell/Th-cell co-cultures and 
was > 80%.
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Th‑cell derived stimuli
BCP-ALL-cells were stimulated with recombinant human 
IL-13 (100 ng/ml), recombinant human TGF-β1 (10 ng/
ml), and recombinant IFN-γ (50 ng/ml, all Peprotech). 
Stimulation with HA-tagged recombinant human CD40 
Ligand (CD40L) (500 ng/ml) was complemented with 
anti-HA antibody (200 ng/ml, both R&D Systems) ena-
bling multimer formation.
siRNA knock‑down
RS4;11 cells were electroporated using the NEON™ 
Transfection System (Thermo Fisher Scientific) with 
Silencer™ Select siRNAs (Thermo Fisher Scientific) tar-
geting RELA (s11916), RELB (s11918), SMAD3 (s8401), 
STAT6 (s13542) and SMAD2 (1:1 ratio of s8397 and 
s8398). A non-targeting siRNA (4390843) was used as a 
negative control.
qRT‑PCR
RNA from primary samples was isolated using Quick-RNA 
Microprep kit (Zymo Research). RNA from cell lines was 
isolated using RNeasy Miniprep kit (Qiagen) with sub-
sequent DNA-free™ Kit treatment (Thermo Fisher Sci-
entific) or Quick-RNA Microprep kit. First strand cDNA 
was generated using High-Capacity cDNA Reverse Tran-
scription Kit (Thermo Fisher Scientific). qRT-PCR was 
performed using TaqMan™ Gene Expression Master Mix 
(Thermo Fisher Scientific) on a CFX384 qPCR system 
(Bio-Rad Laboratories). Gene expression was measured 
using pre-designed assays from Thermo Fisher Scientific 
for AICDA (Hs00757808_m1), UNG (Hs01037093_m1), 
MSH2 (Hs00954125_m1), MSH6 (Hs00943000_m1), 
REV1 (Hs00249411_m1), APEX1 (Hs00172396_m1), 
and POLH (Hs00197814_m1) and from Integrated DNA 
Technologies for POLB (Hs.PT.58.14431563), BCL6 (Hs.
PT.56a.19673829.g), and APEX2 (Hs.PT.58.46813622). 
For primary cells, gene expression was normalized to the 
geometric mean of HMBS (Hs00609297_m1, Thermo 
Fisher Scientific), GUSB (Hs.PT.58v.27737538), TBP (Hs.
PT.39a.22214825) and YWHAZ (Hs.PT.39a.22214858, all 
Integrated DNA Technologies) using the dCT method. For 
cell lines, AICDA expression was normalized to the geo-
metric mean of HMBS and GUSB using the ddCT method. 
The stability of endogenous control combinations was pre-
validated using the R package NormqPCR_1.30.0 [19]. 
For early experiments, gene expression was normalized to 
HMBS only, and qRT-PCR was performed on a 7900HT 
qPCR system (see Figure legends, Thermo Fisher Scientific).
Pre‑amplification
Due to the low RNA yield of primary samples, targets 
were pre-amplified using TaqMan™ PreAmp Master 
Mix (Thermo Fisher Scientific). Unbiased target gene 
pre-amplification was pre-validated. Pre-amplification of 
genes detected at CT ≥ 35 before pre-amplification was 
unreliable. Therefore, limit of detection (LOD) was set to 
 LODExperiment = 35–cyclegainExperiment. Experiment specific 
cycle gain was determined with a sample analyzed before 
and after pre-amplification. CTs ≥ LOD were replaced with 
 LODExperiment.
ELISA
Th-cell IL-13 secretion was measured after CD3/CD28 
stimulation in cRPMI with 20 U/ml IL-2 using the Human 
IL-13 Uncoated ELISA kit (Invitrogen). TGFβ secretion was 
measured after CD3/CD28 stimulation in serum-free AIM 
V® medium (gibco) with 20 U/ml IL-2 using the Human/
Mouse TGF beta 1 Uncoated ELISA kit (Invitrogen).
Flow cytometry
Th-cells were stained with Zombie Red viability dye, 
anti-CD19-BV421 (HIB-19), anti-CD4-APC-FIRE (RPA-
T4) (all  Biolegend®) and anti-CD40L-APC (24–31, eBio-
science™) or appropriate isotype control. Cells were fixed 
using BD CytoFix/CytoPerm™ (BD Biosciences) and 
acquired on BD LSR Fortessa (BD Biosciences).
Tonsillar naïve and GC B-cells were sorted as follows: 
Tonsillar B-cells were isolated as described [18]. Naïve 
B-cells  (CD3−  CD19+  CD38low  IgD+) and GC B-cells 
 (CD3−  CD19+  CD38high  IgD−) were sorted using BD FAC-
SAria™ Fusion (BD Bioscience) after staining with Zombie 
Red viability dye, anti-CD3-FITC (UCHT-1), anti-CD19-
BV421 (HIB-19), anti-IgD-APC (IA6-2, all Biolegend) and 
anti-CD38-PE (HIT2, BD Biosciences). The purity after the 
sort was at least 84%.
Western blotting
For total protein extraction, cells were lysed in urea lysis 
buffer [8 M Urea, 0.5% Triton-X, cOmplete Tablet Mini, 
PhosphoStop (both Roche Diagnostics)]. Cellular fractiona-
tion lysates were prepared as described [20], complemented 
with longer centrifugation and washing of the nuclear pellet 
for higher purity. Proteins were separated on 4–12% NuPage 
Gels (Thermo Fisher Scientific) and transferred to nitrocellu-
lose membranes (GE Healthcare Life Science). Primary anti-
bodies against AID (#4949), β-actin (#4967), p65 (#4764), 
p100/p52 (#4882), RelB (#4922), αTubulin (#3873, all Cell 
Signaling Technologies), Smad2/3 (GTX111123), Stat6 
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(GTX113273, both GeneTex) and Phospho-Stat6 (686002, 
 Biolegend®) were used. Primary antibodies were detected 
using HRP-labeled secondary antibodies (Cell Signaling 
Technologies) and Amersham ECL™ Western Blotting rea-
gent (GE Healthcare Life Science) or Supersignal™ West 
Femto Maximum Sensitivity Substrate (Thermo Fisher 
Scientific) using a ChemiDoc Imaging System (Bio-Rad 
Laboratories).
Microarray analysis
Microarray data were published before [21] (accession 
GSE13576). AICDA gene expression in patients without 
relapse, with relapse before 24 months, and relapse after 
24 months was analyzed.
St. Jude patient samples
To analyze the presence of AID mutational signature, whole-
genome sequencing (WGS) data generated by the St. Jude 
Children’s Research Hospital—Washington University Pedi-
atric Cancer Genome Project were used [22]. See Table 1 for 
clinical patient data.
Mutational signatures
Single-nucleotide variants (SNVs) from WGS data were 
called by the St. Jude in-house somatic variant analysis pipe-
line. Mutational signature analysis was performed by fitting 
the signatures SBS1-30 [23], SBS84, and SBS85 (Cosmic 
version 3 [24]) using the R package MutationalPatterns 
1.10.0 [23]. Refitting quality was assessed using cosine 
similarity by comparing the initial with the reconstructed 
mutation profile. AID-target genes were defined as human 
orthologs of mouse AID off-target genes [25].
Alternative AID‑target genes
Non-synonymous mutations were identified using the R 
package VariantAnnotation 1.30.1 [26] and analyzed for 
their 3 bp context. Mutation frequency within and outside 
the AID-target motif (RC > NY) was compared to the fre-
quency expected by random mutation distribution (motif fre-
quency in the gene sequence). KRAS mutations of other can-
cer types were collected from the COSMIC database [27].
RNA sequencing analysis
For 184 of the patients analyzed for AID activity, RNA 
sequencing data were published before [28] and can be 
accessed at https ://viz.stjud e.cloud /StJud e/visua lizat ion/
pax5-drive n-subty pes-of-b-proge nitor -acute -lymph oblas tic-
leuke mia-heatm ap. AICDA gene expression was analyzed in 
patients with and without BCR-ABL1 translocation.
In vitro AID activity
Reporter construct
To generate the reporter and control constructs [pL40C_
PGKintron_EGFP(Stop)_BSD], constructs previously 
described [pCru5-EGFP(Stop)-IRES-Puro, gift from Mat-
thias Wabl, University of California] [29], were cloned 
into the lentiviral vector pL40C_PGKintron_Cas9_Green 
(Addgene #134966) and puromycin resistance was replaced 
by a blasticidin resistance from pLX-sgRNA (Addgene 
#50662).
Reporter cell line generation
Lentivirus was produced using calcium phosphate trans-
fection of HEK293T cells with pL40C_PGKintron_
EGFP(Stop)_BSD, pVSV-G (Clontech Laboratories) and 
psPax2 (Addgene #12260). RS4;11 EGFP-Stop and EGFP 
were generated by spinoculation with lentiviral supernatant 
and 5 μg/ml polybrene (Merck Millipore). Transduced cells 
were selected in 10 μg/ml blasticidin (InvivoGen) for 6 days 
and further maintained at 5 μg/ml blasticidin.
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Reporter assay
Cells were harvested every fourth day and stained with 
7-AAD  (Biolegend®) for flow cytometric analysis using BD 
LSR Fortessa.
Sanger sequencing
To validate Stop codon reversion, EGFP high, low and nega-
tive cells were sorted using BD FACSAria™ Fusion (BD 
Bioscience) and outgrown. Genomic DNA was isolated 
using  QIAmp® DNA Blood Mini Kit (Qiagen). EGFP was 
amplified using nested PCR with Phusion High-Fidelity 
DNA Polymerase and ligated into  pCR® 2.1 vector (The 
Original TA Cloning Kit, both Thermo Fisher Scien-
tific). Five clones per population were analyzed by Sanger 
sequencing (Microsynth).
Statistical analysis
Statistical analysis was performed using GraphPad Prism 
8.0.3 (GraphPad Software, LLC) or R 3.6.1, as indicated in 
the figure legends.
Results
BM Th‑cells induce AICDA expression 
in BCP‑ALL‑cells
We previously showed that autologous BM Th-cells acti-
vate and support proliferation of BCP-ALL-cells [17]. 
Here, we asked whether such interactions lead to AICDA 
expression in BCP-ALL-cells. Thus, we separated BMMCs 
into BCP-ALL-cells and Th-cells, cultured purified BCP-
ALL-cells alone or with expanded Th-cells, and assessed 
AICDA expression in subsequently purified BCP-ALL-cells 
by qRT-PCR (Fig. 1a). Whereas BCP-ALL-cells cultured 
alone showed AICDA expression close to or below detection 
limit, their co-culture with autologous BM Th-cells resulted 
in significantly higher AICDA expression (Fig. 1b). Thus, 
analogous to their interaction with mature B-cells, Th-cells 
are, in fact, able to induce AICDA expression in BCP-ALL-
cells that derive from B-cell precursors. This expression 
was independent of exogenous Th-cell activation by CD3/
CD28 stimulation, confirming our previous findings that 
BCP-ALL-cells themselves exhibit the potential to activate 
Th-cells.





































Fig. 1  Th-cell co-culture induces AICDA expression in BCP-ALL-
cells. a Scheme of co-culture experiment. b Primary BCP-ALL-cells 
were cultured either alone or in co-culture with expanded autologous 
Th-cells. Th-cells used for co-culture were either rested or stimulated 
using anti-CD3/CD28 beads. AICDA expression in  CD19+ cells was 
determined using qRT-PCR after preamplification of target genes. 
Shown are mean ± SD of dCT values normalized to the geometric 
mean of HMBS, TBP, GUSB and YWAHZ. LCLs were used as a posi-
tive control. Different symbols represent different patients. p values 
were calculated using one-way ANOVA with Tukey correction for 
multiple comparison. p > 0.05 not significant (n.s.), p < 0.01**
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IL‑13, TGFβ and CD40L mediate Th‑cell‑induced 
AICDA expression in BCP‑ALL‑cells
Next, we aimed to identify mediators of Th-cell-induced 
AICDA expression. IL-4, TGFβ, and CD40L are estab-
lished Th-cell-derived inducers of AICDA expression in 
mature B-cells [30]. Our previous cytokine profiling of 
BM Th-cells from BCP-ALL patients revealed high IFNγ 
secretion, but importantly also IL-13 secretion and TGFB1 
gene expression [17]. While IFNγ has not been involved in 
AICDA expression, IL-13 may induce AICDA expression 
similarly to IL-4 [31]. Thus, we performed ELISA to con-
firm high secretion of IL-13 by BM Th-cells (Supplementary 
Fig. 1a). TGFβ was secreted at low concentration, likely 
due to decreased Th-cell viability in serum-free culture and 
thus can be expected to be higher in vivo (Supplementary 
Fig. 1b). Moreover, CD40L surface expression in activated 
Th-cells was reduced upon co-culture with BCP-ALL-cells, 
indicating contact-induced downregulation of CD40L (Sup-
plementary Fig. 1c). Collectively, we showed that BM Th-
cells from BCP-ALL patients express and secrete AICDA-
inducing stimuli.
Then, to test whether these stimuli induce AICDA expres-
sion in BCP-ALL-cells, we stimulated primary BCP-ALL-
cells with a combination of CD40L, IL-13, and TGFβ 
(hereafter abbreviated CIT). Similar to Th-cell co-culture, 
CIT stimulation induced high AICDA mRNA and protein 
expression (Fig. 2a, b). As expected, IFNγ neither induced 
AICDA expression alone nor further increased CIT induced 
AICDA expression. To characterize their individual impacts 
on AICDA expression, we next stimulated four BCP-ALL 
cell lines (RS4;11, TOM1, SD1, and Nalm6) with combi-
nations of CD40L, IL-13, and TGFβ (Fig. 2c, d). In these 
cell lines, which we used due to the limited cell numbers in 
patient samples, AICDA induction was lower than in primary 
BCP-ALL-cells. In both RS4;11 and TOM1 cells, TGFβ, 
and IL-13/CD40L combination had a significant effect on 
AICDA expression, while IL-13 in RS4;11 and CD40L in 
TOM1 had a significant although only moderate effect. In 
SD1 cells, IL-13 and CD40L alone significantly increased 
AICDA expression and had a synergistic effect. Conversely, 
TGFβ alone or in combination with other stimuli did not 
induce AICDA expression in SD1 cells (Fig. 2c, d). IL-13/
CD40L combination also increased AID protein expression 
in SD1 cells (Fig. 2e), while AID protein expression could 
not be detected in TOM1 and RS4;11 cells (not shown). 
Noteworthy, none of the stimuli induced AICDA expression 
in the cell line Nalm6, neither on mRNA nor on protein level 
(not shown). Taken together, we have identified Th-cell-
derived IL-13, TGFβ, and CD40L as important mediators 
of Th-cell-induced AICDA expression in BCP-ALL-cells. 
Nevertheless, the combination of stimuli required for AICDA 
induction and the extend of induction varied between cell 
lines and patient samples, suggesting that different BCP-
ALL subtypes may differ in their response to AICDA-induc-
ing stimuli, or may not upregulate AICDA at all. Due to 
the small number of primary samples and the fact that the 
cell lines used here do not cover all the molecular subtypes 
of pediatric BCP-ALL (such as the most common subtypes 
ETV6-RUNX1 and hyperdiploidy), further studies will be 
needed to assess the impact of the molecular subtype on the 
extend of AICDA upregulation.
Th‑cell‑induced AICDA is transcriptionally regulated 
via canonical NF‑κB, Stat6 and Smad2/3 signaling 
in BCP‑ALL‑cells
Th-cell-induced expression of AICDA in precursor B-cells 
or BCP-ALL-cells has not been described so far. Thus, we 
aimed to characterize the mechanism(s) of AICDA expres-
sion in BCP-ALL-cells to gain further insight into BCP-
ALL pathogenesis. Extensive analysis of the transcriptional 
regulation of AICDA in a murine mature B-cell lymphoma 
cell line had revealed that CD40L, IL-4, and TGFβ induce 
AICDA expression via NF-κB, Stat6 and Smad3/4 signal-
ing, respectively [32]. Therefore, we analyzed the activation 
of above-mentioned transcription factors in two BCP-ALL 
cell lines (SD1 and RS4;11) upon stimulation with different 
combinations of CD40L, IL-13, and TGFβ. As expected, 
CD40L stimulation activated both canonical (p65 nuclear 
localization) and non-canonical (p52 nuclear localization) 
NF-κB pathways in both cell lines (Fig. 3a). TGFβ activated 
Smad3 in RS4;11 but not in SD1 cells, consistent with the 
lack of TGFβ-induced AICDA upregulation in the latter. 
IL-13 activated Stat6 in SD1 cells, as we had hypothesized 
based on the fact that IL-13 and IL-4 share signaling path-
ways [33] (Fig. 3b). Unexpectedly, no Stat6 activation was 
detectable in RS4;11 cells. Next, we functionally assessed 
the importance of Smad3, Stat6, and NF-κB in RS4;11 
cells by siRNA knock-down and subsequent stimulation. 
Knock-down efficiency was validated by western blotting 
(Supplementary Fig. 2). Even though we did not detect 
Stat6 phosphorylation, the combined effect of CD40L and 
IL-13 on AICDA expression seemed to be mediated by Stat6 
(Fig. 3c). Both Stat6 and canonical NF-κB knock-down 
(siRelA) almost completely abrogated combined CD40L/
IL-13-induced AICDA expression, indicating a cross-talk of 
these pathways. The precise role of non-canonical NF-κB 
(siRelB) remained unclear due to incomplete knock-down 
(Supplementary Fig. 2). TGFβ-induced AICDA expression 
was only minimally reduced by Smad3 knock-down. Instead, 
TGFβ also activated Smad2 (Fig. 3a), and Smad2 knock-
down tended to reduce TGFβ-induced AICDA expression 
(Fig. 3c). In conclusion, we suggest that transcriptional regu-
lation of AICDA in BCP-ALL-cells closely resembles its 
regulation in murine mature B-cells.






























































Fig. 2  IL-13, TGFβ and CD40L mediate Th-cell-induced AICDA 
expression in BCP-ALL-cells. a Primary BCP-ALL-cells were 
stimulated with CIT ± IFNγ for 3d. AICDA expression was deter-
mined using qRT-PCR after preamplification of target genes. Shown 
are mean ± SD of dCT values normalized to the geometric mean of 
HMBS, TBP, GUSB and YWAHZ. Different symbols represent differ-
ent patients. p values were calculated using a mixed-effect analysis 
with Sidak correction for multiple comparison. p > 0.05 not signifi-
cant (n.s.), p < 0.01** b Xenograft ALL671 BMMCs were stimulated 
using CIT ± IFNγ for 5d. Total AID protein expression was assessed 
using western blotting. β-actin was used as loading control. Western 
blot of primary cells was performed once. c RS4;11, TOM1 and SD1 
cells were stimulated for 3d using different combinations of CD40L, 
IL-13 and TGFβ. AICDA expression was determined using qRT-PCR. 
Shown are mean ± SD of ddCT values normalized to the geometric 
mean of HMBS and GUSB and to unstimulated cells. Dots represent 
different replicates. d p values in the table were calculated from dCT 
values using three-way ANOVA with Geisser-Greenhouse correction 
for sphericity. e SD1 cells were stimulated using CD40L and IL-13 
for 5d. AID protein expression was analyzed using western blotting. 
α-tubulin was used as loading control. Shown is a representative 
result of five replicates
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AID‑induced mutations are not commonly found 
in BCP‑ALL patient samples
Following demonstration that Th-cells induce AID expres-
sion in BCP-ALL-cells, we searched for evidence of AID 
activity in BCP-ALL patient samples. We hypothesized 
AICDA expression to be associated with higher mutation 
load and worse outcome. Analysis of an existing microarray 
dataset [21], however, showed generally low AICDA expres-
sion, irrespective of the patients’ outcome (Fig. 4a). Never-
theless, AICDA might be expressed only in a small fraction 
of cells at a given time point, and thus escape microarray 
detection while being sufficient to cause pathogenesis-rele-
vant mutations. Therefore, we asked whether, at diagnosis, 
AID-induced mutations are detectable in expanded clones of 
primary BCP-ALL-cells. Thus, we assessed the activity of 
AID and other mutational processes by mutational signature 
analysis in WGS data of 243 BCP-ALL patients. Our refit-
ting approach identified similar signature contributions as 
previously identified by de novo mutational signature extrac-
tion [34] (Fig. 4b). Analysis of the contribution of AID-asso-
ciated signatures 9, 84, and 85, however, suggested that AID 
does not lead to widespread mutagenesis. Nevertheless, due 
to its localized action, AID activity is often detected only in 
(off-)target genes and in regions with clustered mutations [8, 
11, 35]. Accordingly, we next assessed mutational signature 
contribution in clustered mutations, defined as two muta-
tions localized within 1000 bp. Low numbers of clustered 
mutations (median = 10) led to a low refitting quality. We, 
therefore, restricted our analysis to patient samples with a 
cosine similarity > 0.75 (Fig. 4c). In these samples, most 
clustered mutations were caused by APOBEC3 mutagenesis 
(Signatures 2 and 13) (Fig. 4d), known to induce clustered 
mutations [36]. Additionally, we detected signature 7, likely 
due to its induction of CC > TT mutations. Collectively, 
we successfully identified signatures that typically induce 
clustered mutation. Nonetheless, we found canonical AID 
activity (Signature 84) in patient sample SJBALL02137 
Fig. 3  Th-cell-induced AICDA is transcriptionally regulated via 
canonical NF-κB, Stat6 and Smad2/3 signaling in BCP-ALL-cells. a, 
b RS4;11 and SD1 cell lines were stimulated for 2  h with CD40L, 
IL-13 and TGFβ. a Localization of transcription factors in cyto-
plasmic and nuclear fraction was analyzed using western blotting. 
α-Tubulin and Lamin A/C were used as a loading and fractionation 
controls. RS4;11 cells do not express Lamin A/C. b Phosphoryla-
tion of Stat6 was analyzed using western blotting. β-actin was used 
as a loading control. c Transcription factors were knocked-down in 
RS4;11 cells by electroporation of siRNA for 48  h and stimulated 
with CD40L, IL-13 or TGFβ for 24  h. AICDA expression was ana-
lyzed using qRT-PCR. Shown are ddCT normalized to HMBS and 
siCtrl/unstimulated condition. p values were calculated using a 
mixed-effect analysis by comparing siCtrl and with targeting siRNA 
with same stimulation. Sidak correction for multiple comparison was 
used. p > 0.05 not significant (n.s.), p < 0.05*, p < 0.01**, n.a. not 
analyzed
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(Fig. 4d), where we identified a kataegic region on chro-
mosome 9 comprising 40 C > T mutations in the CDKN2B 
locus. 40% of these mutations were in the RC > NY motif 
(Fig. 4e). Notably, CDKN2B is an AID target and is often 
inactivated in BCP-ALL patients [14, 37, 38]. Therefore, 
AID seems to induce relevant mutations only in rare cases.
Next, we analyzed mutations in Ig loci and described 
AID off-target genes [25] (Fig. 4c). As shown by the cosine 
similarity, the even lower number of mutations made 
mutational signature refitting unreliable. Since AID off-
target gene mutation depends on high transcription [39], 
AID may not target the same genes in BCP-ALL-cells that 
were described to be off-targets in mature B-cells. Thus, 
we aimed to identify non-synonymous mutations targeted 
by AID. We found that the AID-target motif (RC > NY) 
was significantly enriched in KRAS mutations (Fig. 4f, g), 
but the same target motif was enriched in KRAS muta-
tions in the COSMIC database, mostly representing 
mutations in non-B-cell malignancies (Fig. 4g). Moreo-
ver, KRAS mutations are restricted to a few hotspots [40]. 
This suggests that functionally relevant base pairs rather 
than mutational processes determine the context of KRAS 
mutations. Overall, while a rare AID mutational activity 
cannot be excluded, our analysis showed no detectable 
contribution of AID activity to the mutational profile in 
BCP-ALL patient samples.
AID‑induced mutations and AICDA expression are 
not enhanced in BCR‑ABL1 BCP‑ALL
Previous studies suggest that particularly BCP-ALL 
patients of the BCR-ABL1 subtype exhibit high AICDA/
AID expression and activity [13, 14, 37, 41]. Thus, we 
aimed to assess the relative contribution of AID-associated 
mutational signatures in BCR-ABL1 versus other subtypes 
in our cohort and found a similar contribution of AID-
associated mutational signatures to total genome mutations 
in both groups (Fig. 4h). BCR-ABL1 BCP-ALL samples 
harbored too few clustered mutations (median = 9) for reli-
able mutational signature analysis, and none of the muta-
tion clusters in BCR-ABL1 BCP-ALL contained multiple 
WRC > NY hotspot mutation (and neither less restrictive 
RC > NY nor WRC > N motifs), indicating that muta-
tion clusters arose by different mutational processes (not 
shown). In contrast to previous studies [37, 41], published 
RNA sequencing data of 184 of the patients analyzed for 
AID activity did not reveal an increased AICDA expres-
sion in BCR-ABL1 BCP-ALL compared to other sub-
types (Fig. 4i) [28]. In conclusion, we did not observe an 
increased AID activity in BCR-ABL1 BCP-ALL patients, 
which might be explained by a lack of increased AICDA 
expression in our cohort.
High‑fidelity repair and lack of protection 
from DNA‑damage‑induced cell death by BCL6 
might explain lack of AID activity in BCP‑ALL 
patients
AID-mediated mutagenesis is initiated by AID-induced cyti-
dine deamination and is followed by the recruitment of and 
processing by repair proteins. Depending on the recruited 
proteins, deaminated sites may be repaired with low-fidelity, 
resulting in mutations, or may be correctly repaired by high-
fidelity pathways. Accordingly, mature B-cells entering the 
GC upregulate genes involved in base-excision and mis-
match repair, low-fidelity polymerases, and down-regulate 
high-fidelity polymerases to increase mutation frequency 
[42]. Expression of these genes by BCP-ALL-cells, how-
ever, is not known. Since lack of AID-induced mutations in 
BCP-ALL patient samples despite high AICDA induction 
by Th-cells in vitro could be due to insufficient expression 
of repair proteins, we assessed expression of those genes in 
BCP-ALL-cells co-cultured with Th-cells. BCP-ALL co-cul-
tured with Th-cells expressed most of the analyzed genes at 
a similar level as GC B-cells (Fig. 5). Interestingly, however, 
Th-cell-stimulated BCP-ALL cells showed lower polymer-
ase η (POLH) (low-fidelity) and significantly higher poly-
merase β (POLB) (high-fidelity) expression compared to GC 
B-cells, which may explain the lower mutation frequency 
despite AICDA expression. Additionally, B-cell lymphoma 
6 protein (BCL6) expression was significantly lower in Th-
cell-stimulated BCP-ALL-cells than in GC B-cells. Whereas 
BCL6 is not directly involved in the repair of AID-induced 
mutagenesis, it increases the survival of cells undergoing 
mutagenesis [43, 44]. Thus, AID-induced mutations in BCP-
ALL-cells may both be repaired at a higher fidelity as well 
as lead to DNA damage-induced cell death, which possibly 
explains a low rate of AID-induced mutations despite high 
AICDA expression.
AID seems to be active in BCP‑ALL‑cells in vitro
To further investigate the activity of Th-cell-induced AID in 
BCP-ALL-cells, we generated an RS4;11 reporter cell line, 
where AID activity leads to the reversion of a premature 
Stop codon and thereby to EGFP translation (Fig. 6a). After 
transduction, we observed three populations: one with no, 
one with low and one with high EGFP expression. Sanger 
sequencing of the sorted populations showed that only the 
 EGFPhigh but not the  EGFPlow population arose by stop 
codon reversion (Fig. 6b). CIT stimulation of one reporter 
cell line led to an increase of the  EGFPhigh population, sug-
gesting induction of mutagenic activity (Fig. 6c, d). Nev-
ertheless, no such mutagenic activity could be observed in 
six newly generated reporter cell lines (not shown). These 
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results imply that, even though Th-cell stimulation of BCP-
ALL-cells in vitro can cause mutations, this is likely to be 
a very rare event—similar to what we observed in patient 
samples.
Discussion
Inappropriate immune response to delayed infections has 
been proposed to trigger development of overt leukemia. 
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We previously showed that Th-cells, which migrate to the 
BM after infections, promote activation and prolifera-
tion of BCP-ALL-cells, suggesting that Th-cells are the 
link between infection and overt leukemia [17]. Here, we 
expand our model and show that this supportive interac-
tion includes induction of high AICDA expression by a 
mechanism similar to that in mature B-cells. Furthermore, 
we found that this expression is not reflected in AID off-
target mutations in patient samples, implying that AID is 
unlikely to be involved in the development of BCP-ALL. 
Our results add to the understanding of BCP-ALL patho-
genesis and the identification of potential therapeutic 
targets.
Rare AICDA expression in healthy precursor B-cells—at 
least in mice—seems to be Th-cell-independent and rather 
caused by toll-like receptor signaling [45]. Our demonstra-
tion that BM Th-cells are able to induce AICDA expression 
in human (malignant) precursor B-cells in vitro through 
mediators and mechanisms similar to those in mature B-cells 
in GC is unprecedented. This may also be relevant for other 
B-cell malignancies, such as CLL, where subclonal AID 
expression and activity have been reported in a CLL sub-
set associated with bad outcome [8]. Interestingly, Th-cells 
interact with CLL-cells, and microarray analysis suggested 
that this leads to AICDA upregulation in CLL-cells ([46] and 
personal communication).
Our previous [17] and current work strongly suggests 
that Th-cells support BCP-ALL-cells and induce AICDA 
expression independently of CD3/CD28 stimulation. Thus, 
(pre)leukemic cells may incite Th-cell-dependent AID-
induced mutagenesis by a (neo)antigen-dependent inter-
action. Whereas most AID-induced off-target mutations 
may not affect (pre)leukemic cells, some mutations may 
lead to a survival advantage, clonal expansion and leuke-
mia progression. To elucidate whether BCP-ALL-cells may 
indeed acquire such AID-mediated survival advantages, we 
Fig. 4  AID-induced mutations are not commonly found in BCP-ALL 
patients samples. a AICDA expression was analyzed by microarray 
in xenografts generated from diagnostic samples of patients with no, 
relapse after 24 months and relapse before 24 months. AICDA expres-
sion for each patient and mean ± SD are shown. p values were cal-
culated using one-way ANOVA with Tukey correction for multiple 
comparison. p > 0.05 not significant (n.s.), b–d Values of each patient 
and median values are shown. b Relative contribution of mutational 
signatures to mutations in total genome was assessed using R pack-
age MutationalPatterns in WGS data. c Cosine similarity of original 
mutation profile compared to the reconstructed mutation profile. d 
Relative contribution of mutational signatures to clustered muta-
tions is shown for patients with cosine similarity > 0.75. Relative 
contribution in patient SJBALL021373 is depicted in red. e Rainfall-
plot of mutations in patient SJBALL021373 was generated using R 
package karyoploteR. f Table of genes with most mutations in AID 
motif (RC > NY). p values were calculated using Fisher’s exact test 
by comparing observed mutations  (nmut in RCY) to expected AID 
motif mutations for each gene according to the frequency of AID 
motif in each gene (% RCY in gene). Genes with statistically sig-
nificant enrichment of AID motif mutations after Benjamini–Hoch-
berg correction are depicted in bold. g Frequency of AID motif 
mutations in KRAS in BCP-ALL patients, in COSMIC database and 
according to distribution of motif in KRAS sequence. p values were 
calculated using Fisher’s exact tests. p > 0.05 not significant (n.s.), 
p < 0.0001**** . h Relative contribution of mutational signatures to 
mutations in total genome was assessed using R package Mutational-
Patterns in WGS data. p values were calculated using Kruskal–Wal-
lis test and Dunn’s test for multiple comparison p > 0.05 not signifi-
cant (n.s.). i AICDA expression was analyzed by RNA sequencing in 
pediatric BCP-ALL patients. Values for each patient and median are 
shown. p values were calculated using Mann–Whitney test. p > 0.05 
not significant (n.s.)
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Fig. 5  High-fidelity repair and lack of protection from DNA-damage-
induced cell death by BCL6 might explain lack of AID activity in 
BCP-ALL patients. Tonsillar B-cells were sorted into naïve  (CD19+ 
 CD3−  IgD+  CD38−) and GC  (CD19+  CD3−  IgD−  CD38+) B-cells. 
Primary BCP-ALL-cells were treated as in Fig. 1b. Gene expression 
in  CD19+ cells was determined using qRT-PCR after preamplifica-
tion of target genes. Shown are mean ± SD of dCT values normalized 
to the geometric mean of HMBS, TBP, GUSB and YWAHZ. p val-
ues were calculated using Brown-Forsythe and Welch ANOVA test 
with Dunnett’s T3 test for multiple comparisons by comparing gene 
expression in GC B-cells and BCP-ALL-cells co-cultured with Th-
cells. p > 0.05 not significant (n.s.), p < 0.05*, p < 0.01**
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searched for evidence of AID activity in BCP-ALL patients 
employing three strategies: (1) mutational signature analysis 
in clustered mutations, (2) analysis of mutations in known 
AID-target genes, and (3) identification of alternative AID-
target genes in the precursor B-cell context. None of the 
approaches provided evidence for extensive AID activity 
in BCP-ALL patients. This contrasts previous findings in 
BCR-ABL1 and ETV6-RUNX1 preleukemic mouse models, 
where AID accelerates the progression to overt leukemia 
[12, 13].
In contrast to previous studies that detected higher 
AICDA/AID mRNA, protein expression, and activ-
ity in BCR-ABL1 BCP-ALL than in other subtypes [37, 
41], we did not detect such an association in our cohort. 
Interestingly, BCR-ABL1 is more frequent in adult than 
in pediatric patients, and previous studies mostly analyzed 
samples from adult patients for AICDA/AID expression: 
AID protein expression was analyzed in adults only and 
8/10 samples analyzed for AICDA gene expression were 
adults, though age data is not available for 28 additional 
patients [37, 41]. Thus, the mutagenic activity of AID in 
BCR-ABL1 BCP-ALL may be restricted to adult patients 
by a yet unknown mechanism.
AID was further suggested to accelerate the pathogenesis 
of ETV6-RUNX1 BCP-ALL upon the upregulation of AID 
by infectious stimuli. In this model, preleukemic cells were 
repetitively stimulated with LPS ex vivo [12]. In contrast to 
above mouse model, more physiological infectious stimuli 
Fig. 6  AID seems to be active 
in BCP-ALL-cells in vitro. a 
The lentiviral reporter construct 
contains an EGFP-sequence 
with a premature stop codon 
(EGFP-Stop) within the target 
motif of AID (WRCY). AID-
induced mutagenesis and repair 
leads to stop codon reversion 
and to translation of EGFP. b 
RS4;11 cell line was trans-
duced with the EGFP-Stop 
reporter construct or EGFP 
control construct. Cells were 
sorted in  EGFPneg,  EGFPlow 
and  EGFPhigh population and 
outgrown. Sanger sequencing 
was performed to assess the 
reversion of the stop codon. c 
unsorted EGFP-Stop cells were 
cultured unstimulated or with 
CIT. Medium was changed 
every second day. d Quantifica-
tion of  EGFPhigh cells during 
stimulation
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induce overt leukemia in a  Pax5+/– mouse independently of 
AID expression [15]. Thus, even though we cannot rule out a 
role for AID in the formation of structural variants, our data 
using patient samples strongly favors an AID-independent 
pathogenesis in humans.
Lack of AID activity and low basal AID expression 
ex vivo despite the high induction by Th-cells in vitro may 
reflect rare contact between Th-cells and BCP-ALL-cells 
in vivo or inhibition of AICDA upregulation by other cells 
of the leukemic microenvironment. Further research using 
bone marrow biopsies or infection-induced BCP-ALL mouse 
models [5, 6] is required to address whether and how the 
frequency and duration of contacts between Th-cells and 
BCP-ALL-cells correlate with AID expression, and whether 
and how other cells of the leukemic environment affect AID 
upregulation and BCP-ALL-cell proliferation. In addition, 
the majority of AID-induced mutations in preleukemic cells 
may remain undetected as only a minority of mutations may 
provide a survival advantage and result in clonal expansion. 
Nevertheless, the lack of widespread AID activity makes it 
unlikely that AID caused the transforming mutagenic event. 
Moreover, due to the unavailability of human preleukemic 
cells, we analyzed the Th-cell-induced expression of AICDA 
in leukemic cells. Thus, it remains to be determined whether 
Th-cells induce AICDA expression also in preleukemic cells, 
where AID-activity could lead to mutations detectable at 
diagnosis. As TLR-signaling induces AICDA expression 
both in healthy and preleukemic precursor B-cells [12, 15], 
AICDA expression in preleukemic cells may mainly depend 
on their ability to activate Th-cells, possibly by (neo)anti-
gen-presentation. Furthermore, additional stimuli may be 
required to induce mutations in precursor B-cells. Even 
though we found that BCP-ALL-cells expressed most genes 
encoding for repair proteins at a similar level as GC B-cells, 
increased POLB expression could lead to a lower mutation 
frequency [47]. Additionally, BCP-ALL-cells expressed less 
BCL6 than GC B-cells. As one of the most important tran-
scription factors in GC B-cells, BCL6 may regulate co-fac-
tors required for AID activity that where not analyzed here. 
Thus, decreased BCL6 expression in BCP-ALL-cells may 
hinder AID-induced mutagenesis by increased DNA dam-
age-induced cell death [43, 44] and lack of co-factors. Nev-
ertheless, SHM in Ig loci has been detected in different sub-
sets that typically do not show BCL6 expression [12, 37, 48], 
while we did not detect any Ig loci mutations in 50% of our 
patient samples (not shown). The high genomic complex-
ity and homology of the Ig loci require special approaches 
for alignment of WGS data. As we analyzed already called 
single-nucleotide variants, the frequency of Ig loci mutations 
in our study may have been underestimated. Further inves-
tigation will be required to clarify the prevalence of SHM 
in different BCP-ALL subsets and the impact of BCL6 and 
POLB expression on AID activity in BCP-ALL.
In conclusion, our study extends the recent evidence of 
an AID-independent BCP-ALL pathogenesis in mice [15] 
to human patient samples. Thus, AID expression in BCP-
ALL-cells seems to be merely an indicator of a recent sup-
portive interaction by Th-cells that have migrated to the BM 
upon an infection rather than a driver of clonal evolution. 
As a consequence, research aiming at the development of 
novel therapies for BCP-ALL may focus on targeting the 
Th-cell-mediated support of BCP-ALL-cells rather than 
AID-induced effects.
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